We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based biotechnology company Casma Therapeutics has secured $50m in a Series B financing round to support the development of a programme targeting muscular dystrophy treatment.
Casma Therapeutics has named Third Rock Ventures’ Frank Gentile as its chief operating officer. The appointment means Gentile will commit full time to the autophagy startup he helped get off the ground......
Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with Fondazione Telethon, founder of the Telethon Institute of Genetics and Medicine (TIGEM),